Results 91 to 100 of about 11,390 (145)

Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China. [PDF]

Front Pharmacol
Huang W, Li C, Huang Y, Wang C, Zhang Y, Lin Y.   +5 more
europepmc   +1 more source

Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS). [PDF]

Sci Rep
Kang Y, Sun X, Dang DS, Yuan Y.
europepmc   +1 more source

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with <i>PIK3CA</i>-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study. [PDF]

Cancers (Basel)
Loizidis S, Michaelides D, Marcou Y, Kakouri E, Konstantinou I, Constantinidou A, Theophanous-Kitiri S, Papageorgiou E, Michailidou K, Galazi M.   +9 more
europepmc   +1 more source

Biological and computer-aided evaluation of 3-methoxy-13α-estrone-16α-diphenylphosphine oxide as a new antiestrogenic agent. [PDF]

Sci Rep
Bartha S, Germán P, Bózsity N, Puskás LG, Börzsei R, Hetényi C, Zupkó I, Mernyák E, Minorics R.   +8 more
europepmc   +1 more source

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1. [PDF]

ESMO Open
Vaklavas C, Oliveira M, Armstrong AC, Moreno I, Twelves C, Victoria Ruiz I, Bermejo de Las Heras B, Brier T, Ciardullo C, Gibbons L, Jack T, Klinowska T, Lindemann JPO, Mathewson AM, Maudsley R, Morrow CJ, Sykes A, Baird RD.   +17 more
europepmc   +1 more source

Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies. [PDF]

Breast Cancer (Dove Med Press)
Pogoda K, Pawlik H, Balata A, Czopowicz M, Bak A, Twardowska I, Meluch M, Wojda M, Mlodzinska A, Szombara E, Sienkiewicz R, Konieczna A, Brewczynska E, Lemanska I, Majstrak-Hulewska A, Gorniak A, Niwinska A, Nowecki Z.   +17 more
europepmc   +1 more source

Selective Estrogen Receptor Degraders Induce Bradycardia by Modulating Nuclear Estrogen Signaling. [PDF]

JACC Basic Transl Sci
Basu S, Rosas Diaz AN, Narvaez-Paliza JM, Curtin C, Kurella S, Urias M, More Verde L, Patel JM, Asnani A.   +8 more
europepmc   +1 more source

Vulvar Metastasis from Breast Cancer Treated with Abemaciclib plus Fulvestrant: A Case Report. [PDF]

Case Rep Oncol
Vanden Berghe C, Laka Antxustegi A, Nicaise N, Vander Borght T, D'Hondt L, Moerman J, de Codt M.   +6 more
europepmc   +1 more source

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Rugo HS, Kaklamani V, McArthur H, Wander SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E, Maitland J, Kloss S, Wasserman T, Tolaney SM.   +12 more
europepmc   +1 more source

Fulvestrant Regimen [PDF]

, 2020
openaire   +1 more source